MYC and B-cell non-Hodgkin lymphoma: Among them, CPI203 showed an improved bioavailability when compared to its precursor [64,65] together with a remarkable antitumoral activity in different preclinical models of B-cell non-Hodgkin lymphomas (B-NHLs), including MCL [66], DLBCL [67,68], MM [69], and MYC+/BCL2+ double hit lymphoma [70].